Clinical trial · Interventional
NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy
N-acetyl-L-cysteine for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy--a Prospective Single-arm Clinical Study
NCT06024031CI-TRIAL-00082332active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective single-arm clinical study to evaluate the role of NAC after chemotherapy among patients with AML can promote hematopoietic recovery and does not affect the remission rate of the leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| N-acetyl-L-cysteine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- NAC group
- description
- Low, intermediate risk AML patients were enrolled, and NAC (400mg tid) was administered orally from day1 to day 28 (D1-D28) after the end of induction chemotherapy.
- interventionNames
- Drug: N-acetyl-L-cysteine
Primary outcomes (1)
- measure
- Time to hematopoietic recovery post chemotherapy
- timeFrame
- Participants will be followed for 2 months post induction chemotherapy
- description
- Time to hematopoietic recovery (white blood cell \> 1×10\^9/L, platelet \> 20 ×10\^9/L), the dosages of G-CSF, red blood cell transfusion,platelet transfusion.
Secondary outcomes (4)
- measure
- complete remission rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. Newly diagnosed AML (except AML-M3) 2. Low-, intermediate risk AML (according to 2022 ELN) 3. Aged 18-60 4. No severe organ injury 1) Creatinine \< 1.5mg/dl 2) Hemobilirubin ≤ 1.5 X ULN 3) AST and ALT ≤ 3.0 X ULN 4) Cardiac ejection index ≥ 50% 5. No uncontrolled active infections 6. Sign informed consent form, have the ability to comply with study and follow-up procedures Exclusion Criteria: 1. Hypersensitivity to NAC 2. History of bronchial asthma
References
Publications (1)
- DERIVEDHu LJ, Li CY, Xing T, Wang Y, Jiang Q, Jiang H, Wang J, Tang FF, Chang YJ, Zhang XH, Kong Y, Huang XJ. N-acetyl-L-cysteine promoted hematopoietic recovery in patients with acute myeloid leukemia after complete remission--A pilot study. Cancer Lett. 2025 Aug 10;625:217812. doi: 10.1016/j.canlet.2025.217812. Epub 2025 May 20. PMID 40403956